AbbVie (ABBV) to Showcase Scientific Innovation, Research Advancements Across Dermatology Portfolio at AAD


News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.


AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced it will present 19 abstracts during the 2019 American Academy of Dermatology (AAD) Annual Meeting, March 1-5, in Washington, D.C., including new data from the psoriasis pivotal trials for risankizumab, an investigational interleukin-23 (IL-23) inhibitor.

Investigators will highlight risankizumab response over time across various psoriasis patient subgroups in the first integrated efficacy analyses of ultIMMa-1 and ultIMMa-2, two replicate trials comparing risankizumab to STELARA® (ustekinumab) or placebo. Additionally, AbbVie will present up to 40 months of safety data for risankizumab, as well as longer-term data from IMMvent, a trial exploring the efficacy of switching to risankizumab versus continued HUMIRA use in moderate to severe psoriasis patients with varying levels of intermediate response to HUMIRA after 16 weeks.

“We look forward to sharing the latest research from our growing immunology portfolio at AAD, including data on risankizumab that will add to the body of evidence supporting its potential as a future treatment option for patients living with psoriasis,” said Marek Honczarenko, M.D., Ph.D., vice president, global immunology development, AbbVie. “The breadth of research we are presenting underscores AbbVie’s continued efforts to advance the standard of care and improve treatment expectations for patients living with chronic dermatologic conditions, many of whom still struggle to achieve and maintain their desired treatment goals.”

AbbVie will also share results from a Phase 2b trial evaluating upadacitinib, an investigational oral JAK1-selective inhibitor, in patients with moderate to severe atopic dermatitis. Additional presentations on HUMIRA will validate hidradenitis suppurativa patient-reported outcome measures, assess its efficacy in nail psoriasis among patients with and without psoriatic disease and highlight nine-year registry data evaluating its long-term safety and efficacy in patients with psoriasis.

Risankizumab and upadacitinib are not approved, and their safety and efficacy have not been established by regulatory authorities.

Risankizumab Abstracts

  • Efficacy and Safety of Continuous Q12W Risankizumab Versus Treatment Withdrawal: Results from the Phase 3 IMMhance Trial. Langley et al. Oral Presentation; Friday, March 1, 2019, 12:00-12:05 p.m. EST
  • Efficacy and Safety of Continuous Risankizumab or Switching from Adalimumab to Risankizumab Treatment in Patients with Moderate-to-Severe Plaque Psoriasis: Results from the Phase 3 IMMvent Trial. Reich et al. Oral Presentation; Friday, March 1, 2019, 12:05-12:10 p.m. EST
  • Efficacy of Switching to Risankizumab Compared with Continued Adalimumab Treatment in Patients with Moderate-to-Severe Plaque Psoriasis. Ryan et al. Oral Presentation; Friday, March 1, 2019, 12:15-12:20 p.m. EST
  • Durable Efficacy of Risankizumab Compared with Ustekinumab Across Subgroups of Patients with Moderate-to-Severe Plaque Psoriasis: Integrated Analysis of Two Phase 3 Trials. Foley et al. Oral Presentation; Friday, March 1, 2019, 12:50-12:55 p.m. EST
  • Malignancy Rates in Patients with Moderate to Severe Psoriasis During Treatment with Risankizumab: Analysis of Pooled Clinical Trial Data. Reich et al. Oral Presentation; Sunday, March 3, 2019, 1:30-1:35 p.m. EST
  • Efficacy and Safety of Risankizumab in Moderate to Severe Plaque Psoriasis: An Integrated Analysis of UltIMMa-1 and UltIMMa-2. Lebwohl et al. Eposter
  • Long-term Safety of Risankizumab in Patients with Moderate to Severe Psoriasis: Analysis of Pooled Clinical Trial Data. Leonardi et al. Eposter
  • Risankizumab Treatment is Associated with Low and Consistent Infection Rates Over Time in Patients with Moderate to Severe Psoriasis: Analysis of Pooled Clinical Trial Data. Strober et al. Eposter
  • Exposure-Response Relationships for Efficacy and Safety of Risankizumab in Patients with Moderate to Severe Plaque Psoriasis: Integrated Analyses of Phase 2 and 3 Clinical Trials. Khatri et al. Eposter
  • Safety and Efficacy Results from the Open Label Extension of a Phase 2 Trial of Risankizumab, a Selective IL-23p19 Inhibitor in Patients with Active Psoriatic Arthritis. Papp et al. Eposter

HUMIRA Abstracts

  • ESPRIT Registry Nine-Year Interim Real-World Safety, Effectiveness, and Patient-Reported Outcomes of Adalimumab for Moderate to Severe Psoriasis. Wu et al. Eposter
  • Efficacy of Adalimumab in Nail Psoriasis by History of Psoriatic Arthritis and Overall Safety from Final, Open-Label 26 Weeks of a Phase-3, Randomized, Placebo-Controlled Trial. Elewski et al. Eposter
  • Efficacy of Adalimumab in Nail Psoriasis by Baseline Subgroups, and Overall Safety from First 26 Weeks of a Phase-3, Randomized, Placebo-Controlled Trial. Rich et al. Eposter

Upadacitinib Abstract

  • Upadacitinib Treatment Withdrawal and Retreatment in Patients with Moderate-to-Severe Atopic Dermatitis from a Phase 2b, Randomized, Controlled Trial. Guttman-Yassky et al. Eposter

HEOR (Health Economic and Outcomes Research) Abstracts

Psoriasis

  • Assessing the Impact of Patient Support Programs in Adalimumab-Treated Adults with Psoriasis in Europe. Ryan et al. Oral Presentation; Friday, March 1, 2019, 4:30-4:35 p.m. EST
  • Bridging the Gap between Clinical Trials and Real-World Practice: Predicting Psoriasis Area Severity Index Scores (PASI) Based on Body Surface Area (BSA) and Physicians Global Assessment (PGA). Armstrong et al. Oral Presentation; Friday, March 1, 2019, 4:50-4:55 p.m. EST
  • Long-Term Safety Profile of Adalimumab versus Ustekinumab in Psoriasis – A Real World Matching-Adjusted Indirect Comparison (MAIC). Wu et al. Oral Presentation; Saturday, March 2, 2019, 12:10-12:15 p.m. EST
  • The Comparative Efficacy for Novel Treatments of Moderate to Severe Plaque Psoriasis: A Network Meta-Analysis. Armstrong et al. Oral Presentation; Sunday, March 3, 2019, 2:00-2:05 p.m. EST

Hidradenitis Suppurativa

  • Score Interpretation of the Hidradenitis Suppurativa Symptom Assessment (HSSA) and Hidradenitis Suppurativa Impact Assessment (HSIA). Kimball et al. Oral Presentation; Saturday, March 2, 2019, 1:25-1:30 p.m. EST

The 2019 AAD Annual Meeting abstracts are available here.

Source link

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *